



# *Hedge Funds Market Update*

*Q4 2021*

*For professional  
investors only*

*Pictet Alternative Advisors*



## MACRO


The quarter was challenging for the discretionary Macro strategy. In October managers were hit when the flattening of the yield curve disrupted the popular bet that long-term yields will rise more quickly than shorter-term ones as the world economy continues to recover from the pandemic. Keeping a reflationary outlook through steepeners, this positioning generated losses following a hawkish turn by the BoE governor, a movement which then spread to other developed regions. Commodities, with long positions across the energy complex were generally a source of gains. In December risk levels were brought down due to a lack of visibility from central banks, the impact of the omicron variant and year end lack of liquidity. Systematic trading managers had a mixed quarter. The strategy started the quarter in positive territory but the situation deteriorated as prevailing trends in equities, fixed income and commodities all reversed sharply during November. At the end of the year, most traditional trend-followers registered losses as gains in equity indices were outweighed by losses in the remaining asset classes. In contrast, managers focusing on more niche markets or employing a multi-strategy approach in the quantitative space were able to finish in positive territory for the month and for the year.

## EQUITY HEDGE

After a sharp decline in November, developed-market equities hit a new record high at the end of December, brushing off worries of the new Covid variant Omicron. Despite the strong returns for the broad market indices, Equity Hedge managers across the board suffered from sharp rotations in several segments of the Technology market amid rising bond yields. This rotation impacted all regions but it was especially difficult to navigate for specialists on the technology sector, irrespective of their level of net exposure. Managers with a bias towards cyclicals and growth underperformed, whereas managers with a market neutral stance or a value bias generally performed better.


## EVENT DRIVEN

During the fourth quarter, Event-Driven managers did well across its spectrum of activists, special situations and merger arbitrage managers. Activist managers benefitted from idiosyncratic stories as well as from the tailwind of a positive equity market backdrop in December. A traditional rush to get deals done before the end of the year saw more than \$500 billion in transactions announced in December alone. Merger arbitrage specialists also benefited from a spreads compression thanks to US presidential election relief rally and Covid19 vaccine news. Some of the largest transactions include Home Depot acquiring its former subsidiary, HD Supply Holdings at a 28% premium in November (approx. \$9bn transaction) and Advanced Micro Devices Inc. buying Xilinx Inc. Within credit-related Event-Driven managers, high-yield bonds provided their strongest returns of 2021 in December as concerns around the Omicron variant receded. Overall, US default activity was extremely modest in 2021, with 13 companies defaulted and debt totalling \$10.4bn in bonds and loans, while an additional 8 companies completed distressed transactions totalling \$2.6bn. The yearly combined amount of \$13.0bn inclusive of distressed exchanges ranks as the lightest in a calendar year since \$4.5bn defaulted in 2007.



## RELATIVE VALUE

Relative Value managers produced mixed results over the reporting period. At the beginning of the quarter, inflation overshoot and the unexpected change in tone by central banks triggered a sharp move up at the front end of the US, UK and European yield curve, thereby impacting steepeners positions. Volatility on the front end soared too, which hurt managers with short positions hedged with volatility further down the curve. Overall, multi-portfolio managers with a significant equity exposure performed well, with healthcare, materials, consumer staples and industrials leading the gains. Healthcare in particular was a good source of profit mainly thanks to the short side as some biotechnology names dropped due to several clinical trial data announcements that failed to meet desired endpoints. SPAC arbitrage ended the year as the worst strategy. Discount to trust value widened across the board as the market had difficulty in digesting the continuing flow of new deals and as muted price reaction following deal announcement disappointed investors.





*Pictet Alternative Advisors (PAA) is a leading European alternative investment specialist with expertise in manager selection and portfolio management in liquid alternatives, private equity and real estate. PAA is an independent unit of the Pictet Group. Founded in 1991, we currently manage over USD 30 billion and our team is composed of 100 people.*

---

Pictet Alternative Advisors  
Route des Acacias 60  
1211 Genève 73  
+41 58 323 23 23

---

*[www.alternatives.pictet](http://www.alternatives.pictet)*

#### Disclaimer

This document is not intended for persons who are citizens of, domiciled or resident in, or entities registered in a country or a jurisdiction in which its distribution, publication, provision or use would violate current laws and regulations. In particular, investment funds or any other collective placement instruments which have not been authorised for public offering in the investor's country of domicile may only be offered as private placements to qualified investors. Additional investment restrictions may be provided for in the official offering documentation (available upon request). The information and data furnished in this document are disclosed for information purposes only; the Pictet Group is not liable for them nor do they constitute an offer, an invitation to buy, sell or subscribe to securities or other financial instruments. Furthermore, the information, opinions and estimates in this document reflect an evaluation as of the date of initial publication and may be changed without notice. Information

and opinions presented in this document have been obtained from sources believed to be reliable, and, although all reasonable care has been taken, the Pictet Group is not able to make any representation as to its accuracy or completeness. The value and income of the securities or financial instruments mentioned in this document are based on rates from the customary sources of financial information and may fluctuate. The market value may vary on the basis of economic, financial or political changes, the remaining term, market conditions, the volatility and solvency of the issuer or the benchmark issuer. Moreover, exchange rates may have a positive or negative effect on the value, the price or the income of the securities or the related investments mentioned in this document. Past performance must not be considered an indicator or guarantee of future performance, and the addressees of this document are fully responsible for any investments they make. No express or implied warranty is given as

to future performance. Investors shall conduct their own analysis of the risks (including any legal, regulatory, tax or other consequence) associated with an investment and should seek independent professional advice. The content of this document is confidential and can only be read and/or used by its addressee. The Pictet Group is not liable for the use, transmission or exploitation of the content of this document. Therefore, any form of reproduction, copying, disclosure, modification and/or publication of the content is under the sole liability of the addressee of this document, and no liability whatsoever will be incurred by the Pictet Group. The addressee of this document agrees to comply with the applicable laws and regulations in the jurisdictions where they use the information reproduced in this document. This document is issued by the Pictet Group. This publication and its content may be cited provided that the source is indicated. All rights reserved. Copyright 2020.

© 2019 Hedge Fund Research, Inc. - All rights reserved. HFR®, HFRI®, HFRX®, HFRQ®, HFRU®, HFRL®, HFR PortfolioScope®, WWW.HEDGEFUNDRESEARCH.COM®, HEDGE FUND RESEARCH®, HFR IndexScope™, and HFR Risk Parity Indices™ are the trademarks of Hedge Fund Research, Inc. This information is obtained from sources that Hedge Fund Research, Inc. considers to be reliable; however, no representation is made as to, and no responsibility or liability is accepted for, the accuracy or completeness of the information. Information contained herein is subject to change at any time without notice. It is not possible to invest directly in a financial index. Exposure represented by an index is available through instruments based on that index. HFR does not sponsor, endorse, sell, promote or manage any investment products.